Dr. Edward Wirth served for 7 years as Medical Director, Regenerative Medicine at Geron Corporation (NASDAQ: GERN) and most recently as Chief Science Officer at InVivo Therapeutic. While at Geron he led efforts to initiate human clinical trials of Geron’s application of human progenitor cells to spinal cord injury. Prior to his work with Geron Corporation, Dr. Wirth held appointments at Rush-Presbyterian St. Luke’s Medical Center and at the University of Chicago.
From 1997 to 2002, Dr. Wirth led the team at the University of Florida that performed the first human embryonic spinal cord tissue transplants in the U.S., demonstrating the feasibility and safety of implanting embryonic spinal cord cells into patients. Dr. Wirth received a Ph.D. in neuroscience and an M.D. from the University of Florida, and earned a B.A. in physics from Rollins College in Winter Park, FL.